Reuters -- Biotechnology company Rigel Pharmaceuticals Inc said it was close to signing a partner to pursue development of its experimental psoriasis treatment. “We are continuing to work on R348 as a topical agent for psoriasis. It is likely that in the next three months we will announce a deal on R348,” Chief Operating Officer Raul Rodriguez told Reuters.
